DexCom Management

Management criteria checks 3/4

DexCom's CEO is Kevin Sayer, appointed in Jun 2011, has a tenure of 12.83 years. total yearly compensation is $15.44M, comprised of 6.2% salary and 93.8% bonuses, including company stock and options. directly owns 0.044% of the company’s shares, worth $24.02M. The average tenure of the management team and the board of directors is 3 years and 9.4 years respectively.

Key information

Kevin Sayer

Chief executive officer

US$15.4m

Total compensation

CEO salary percentage6.2%
CEO tenure12.8yrs
CEO ownership0.04%
Management average tenure3yrs
Board average tenure9.4yrs

Recent management updates

Recent updates

Returns At DexCom (NASDAQ:DXCM) Are On The Way Up

Apr 25
Returns At DexCom (NASDAQ:DXCM) Are On The Way Up

Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

Apr 12
Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

DexCom Is Pricey For A Reason - Its Growth Story Reflects That

Apr 11

Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Mar 29
Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Mar 04
Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

DexCom: A Wealth Compounder In Healthcare

Feb 14

DexCom: Stelo Stellar Outlook

Jan 17

DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

Jan 15
DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

Jan 01
DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Dec 18
DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Dec 05
A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?

Nov 21
At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?

DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital

Sep 28
DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital

DexCom (NASDAQ:DXCM) Could Easily Take On More Debt

Sep 13
DexCom (NASDAQ:DXCM) Could Easily Take On More Debt

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Aug 29
Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Aug 14
Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet

Jun 05
DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet

There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

May 16
There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

Mar 21
Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

Mar 03
These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

Feb 13
DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

DexCom (NASDAQ:DXCM) Seems To Use Debt Quite Sensibly

Nov 25
DexCom (NASDAQ:DXCM) Seems To Use Debt Quite Sensibly

Returns Are Gaining Momentum At DexCom (NASDAQ:DXCM)

Oct 21
Returns Are Gaining Momentum At DexCom (NASDAQ:DXCM)

Dexcom launches G7 glucose monitoring system in parts of Europe, Asia

Oct 04

What Is DexCom, Inc.'s (NASDAQ:DXCM) Share Price Doing?

Sep 24
What Is DexCom, Inc.'s (NASDAQ:DXCM) Share Price Doing?

DexCom: A High-Priced Medical Devices Company Remains Stuck In A Downtrend

Sep 21

DexCom promotes technology chief Leach to COO

Aug 31

DexCom (NASDAQ:DXCM) Has A Pretty Healthy Balance Sheet

Aug 01
DexCom (NASDAQ:DXCM) Has A Pretty Healthy Balance Sheet

DexCom stock down ~7% after hours as Q2 results miss expectations

Jul 28

Estimating The Intrinsic Value Of DexCom, Inc. (NASDAQ:DXCM)

Jul 13
Estimating The Intrinsic Value Of DexCom, Inc. (NASDAQ:DXCM)

DexCom: I Wouldn't Buy The Dip

Jul 07

Is It Time To Consider Buying DexCom, Inc. (NASDAQ:DXCM)?

Jun 24
Is It Time To Consider Buying DexCom, Inc. (NASDAQ:DXCM)?

We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

Jun 03
We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

DexCom: Q1'22 Earnings Strong Enough To Maintain Valuation But Not To Increase It

May 01

CEO Compensation Analysis

How has Kevin Sayer's remuneration changed compared to DexCom's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

US$542m

Sep 30 2023n/an/a

US$377m

Jun 30 2023n/an/a

US$358m

Mar 31 2023n/an/a

US$293m

Dec 31 2022US$15mUS$953k

US$341m

Sep 30 2022n/an/a

US$244m

Jun 30 2022n/an/a

US$230m

Mar 31 2022n/an/a

US$258m

Dec 31 2021US$12mUS$900k

US$217m

Sep 30 2021n/an/a

US$577m

Jun 30 2021n/an/a

US$562m

Mar 31 2021n/an/a

US$530m

Dec 31 2020US$14mUS$800k

US$550m

Sep 30 2020n/an/a

US$231m

Jun 30 2020n/an/a

US$205m

Mar 31 2020n/an/a

US$148m

Dec 31 2019US$10mUS$691k

US$101m

Sep 30 2019n/an/a

-US$171m

Jun 30 2019n/an/a

-US$170m

Mar 31 2019n/an/a

-US$130m

Dec 31 2018US$10mUS$601k

-US$127m

Sep 30 2018n/an/a

US$43m

Jun 30 2018n/an/a

-US$5m

Mar 31 2018n/an/a

-US$33m

Dec 31 2017US$8mUS$546k

-US$50m

Compensation vs Market: Kevin's total compensation ($USD15.44M) is about average for companies of similar size in the US market ($USD13.51M).

Compensation vs Earnings: Kevin's compensation has increased by more than 20% in the past year.


CEO

Kevin Sayer (65 yo)

12.8yrs

Tenure

US$15,435,652

Compensation

Mr. Kevin Ronald Sayer has been Executive Chairman of DexCom, Inc. since July 30, 2018. Mr. Sayer has been the Chief Executive Officer of DexCom, Inc. since January 5, 2015 and as its President since June...


Leadership Team

NamePositionTenureCompensationOwnership
Kevin Sayer
Executive Chairman12.8yrsUS$15.44m0.044%
$ 24.0m
Jereme Sylvain
Executive VP4.1yrsUS$3.54m0.0085%
$ 4.6m
Jacob Leach
Executive VP & COO1.7yrsUS$4.43m0.065%
$ 35.4m
Girish Naganathan
Executive VP & CTO1.5yrsUS$4.05m0.0014%
$ 737.1k
Michael Brown
Executive VP & Chief Legal Officer2.3yrsUS$5.78m0.0021%
$ 1.2m
Shelly Selvaraj
Senior VP & Chief Information Officer2.6yrsno data0.0065%
$ 3.6m
Sean Christensen
Director of Corporate Affairs & Head of Investor Relationsno datano datano data
Matthew Dolan
Executive Vice President of Strategy3.1yrsno data0.00058%
$ 316.7k
Leverne Marsh
Executive Vice President of Marketingless than a yearno datano data
Sadie Stern
Executive VP & Chief Human Resources Officer3.6yrsno data0.0056%
$ 3.1m
Steven Pacelli
Executive VP & MD of Dexcom Ventures3yrsUS$3.02m0.022%
$ 11.8m
Donald Abbey
Executive Vice President of Global Business Services7.3yrsUS$2.92m0.043%
$ 23.3m

3.0yrs

Average Tenure

49.5yo

Average Age

Experienced Management: DXCM's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kevin Sayer
Executive Chairman16.4yrsUS$15.44m0.044%
$ 24.0m
Mark Foletta
Lead Independent Director9.4yrsUS$360.42k0.015%
$ 8.1m
Steven Altman
Independent Director10.4yrsUS$314.48k0.013%
$ 7.3m
Eric Topol
Independent Director14.8yrsUS$317.37k0.095%
$ 51.7m
Nicholas Augustinos
Independent Director14.4yrsUS$319.30k0.0086%
$ 4.7m
Bridgette Heller
Independent Director4.6yrsUS$317.37k0.0053%
$ 2.9m
Barbara Kahn
Independent Director13yrsUS$319.30k0.0050%
$ 2.7m
Kyle Malady
Independent Director3.5yrsUS$314.48k0.0028%
$ 1.5m
Karen Dahut
Independent Director3.7yrsUS$317.05k0.0031%
$ 1.7m
Richard Collins
Independent Director7.1yrsUS$317.05k0.0092%
$ 5.0m
Rimma Driscoll
Independent Directorless than a yearno datano data

9.4yrs

Average Tenure

62yo

Average Age

Experienced Board: DXCM's board of directors are considered experienced (9.4 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.